WO2019032945A9 - Cd40-binding agents and uses thereof - Google Patents

Cd40-binding agents and uses thereof Download PDF

Info

Publication number
WO2019032945A9
WO2019032945A9 PCT/US2018/046186 US2018046186W WO2019032945A9 WO 2019032945 A9 WO2019032945 A9 WO 2019032945A9 US 2018046186 W US2018046186 W US 2018046186W WO 2019032945 A9 WO2019032945 A9 WO 2019032945A9
Authority
WO
WIPO (PCT)
Prior art keywords
agents
polypeptides
cd40l
fragment
binding agents
Prior art date
Application number
PCT/US2018/046186
Other languages
French (fr)
Other versions
WO2019032945A1 (en
Inventor
Austin L. Gurney
Minu K. SRIVASTAVA
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Publication of WO2019032945A1 publication Critical patent/WO2019032945A1/en
Publication of WO2019032945A9 publication Critical patent/WO2019032945A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Polypeptides and agents that bind human CD40 are disclosed. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising the extracellular domain of CD40L or a fragment thereof, wherein the extracellular domain of CD40L or fragment thereof comprises a mutation in the integrin-binding region. The agents may include bispecific and multispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.
PCT/US2018/046186 2017-08-10 2018-08-10 Cd40-binding agents and uses thereof WO2019032945A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762543734P 2017-08-10 2017-08-10
US62/543,734 2017-08-10

Publications (2)

Publication Number Publication Date
WO2019032945A1 WO2019032945A1 (en) 2019-02-14
WO2019032945A9 true WO2019032945A9 (en) 2019-04-18

Family

ID=65272694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/046186 WO2019032945A1 (en) 2017-08-10 2018-08-10 Cd40-binding agents and uses thereof

Country Status (1)

Country Link
WO (1) WO2019032945A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996731A4 (en) * 2019-07-12 2023-07-12 Op-T Llc Peptides and methods for treating diseases
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2310509T1 (en) * 2008-07-21 2015-07-31 Apogenix Gmbh Tnfsf single chain molecules
MA41460A (en) * 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES

Also Published As

Publication number Publication date
WO2019032945A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
NZ738008A (en) Tigit-binding agents and uses thereof
PH12017501372A1 (en) Tnfrsf-binding agents and uses thereof
WO2019083990A3 (en) IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-α (FAP-α)
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
MX2020003939A (en) Mdm2 inhibitors and therapeutic methods using the same.
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2017014908A (en) Trispecific binding proteins and methods of use.
MX2022010623A (en) Treatment of cancer using anti-cd19 chimeric antigen receptor.
MX2022008523A (en) Glycan-interacting compounds and methods of use.
MX2017005258A (en) Combination therapy for treatment of disease.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2016014647A (en) Ox40l fusion proteins and uses thereof.
MX2022014914A (en) Glycan-interacting compounds and methods of use.
TW201613636A (en) Methods of treating Alzheimer's Disease
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
MX2023007840A (en) Monovalent anti-properdin antibodies and antibody fragments.
MX2018011875A (en) Enhanced direct cardiac reprogramming.
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2019032945A9 (en) Cd40-binding agents and uses thereof
MX2023004314A (en) Therapeutic anti-cd40 ligand antibodies.
MX2020000636A (en) Synthetic proteins and therapeutic uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18843262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18843262

Country of ref document: EP

Kind code of ref document: A1